A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma.
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Unresectable Hepatocellular Carcinoma
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
Inclusion Criteria: 1. Histologically proven locally advanced, metastatic, or unresectable hepatocellular carcinoma that has not received prior systemic therapy. 2. At least 1 untreated measurable lesion according to RECIST 1.1. 3. Willingness to undergo fresh tumor biopsy at baseline if safe and feasible. Note: archival tissue may be used at baseline provided histologic diagnosis was made and sufficient tissue is available for NGS analysis. 4. ECOG Performance Status of 0-1 and Liver Disease that is Category CP-B7.
You may not be eligible for this study if the following are true:
-
Exclusion Criteria: 1. Histologic diagnosis of fibrolamellar or sarcomatoid HCC or mixed cholangiocarcinoma-HCC. 2. Patients who have had chemotherapy, definitive radiation, biological cancer therapy, or investigational agent/device within 21 days of first planned dose of study therapy. 3. Patients who have had major surgery within 4 weeks of start of study therapy or anticipation of need for a major surgical procedure during the study. 4.Patients who have received prior systemic therapy for HCC.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.